BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 12883702)

  • 1. Relationship between AgNORs, MIB-1 and oncogene expression in male breast carcinoma and papillary superficial bladder neoplasm.
    Pich A; Margaria E; Chiusa L; Bortolin P; Palestro G
    Oncol Rep; 2003; 10(5):1329-35. PubMed ID: 12883702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proliferative activity is the most significant predictor of recurrence in noninvasive papillary urothelial neoplasms of low malignant potential and grade 1 papillary carcinomas of the bladder.
    Pich A; Chiusa L; Formiconi A; Galliano D; Bortolin P; Comino A; Navone R
    Cancer; 2002 Aug; 95(4):784-90. PubMed ID: 12209722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
    Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
    J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of the expression of p53, MIB-1 (Ki-67 antigen), and argyrophilic nucleolar organizer regions in carcinoma of the extrahepatic bile duct.
    Suto T; Sugai T; Nakamura S; Funato O; Nitta H; Sasaki R; Kanno S; Saito K
    Cancer; 1998 Jan; 82(1):86-95. PubMed ID: 9428483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Argyrophilic nucleolar organizer region in proliferating cell has a predictive value for local recurrence in superficial bladder tumor.
    Tomobe M; Shimazui T; Uchida K; Hinotsu S; Akaza H
    J Urol; 1999 Jul; 162(1):63-8. PubMed ID: 10379741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bcl-2 protein expression is associated with p27 and p53 protein expressions and MIB-1 counts in breast cancer.
    Tsutsui S; Yasuda K; Suzuki K; Takeuchi H; Nishizaki T; Higashi H; Era S
    BMC Cancer; 2006 Jul; 6():187. PubMed ID: 16839413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder.
    Popov Z; Hoznek A; Colombel M; Bastuji-Garin S; Lefrere-Belda MA; Bellot J; Abboh CC; Mazerolles C; Chopin DK
    Cancer; 1997 Oct; 80(8):1472-81. PubMed ID: 9338472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparative study of P 53, Bcl-2, and C-erbB-2 expression in low-grade papillary bladder tumors].
    Ramos Soler D; Navarro Fos S; Villamón Fort R; Gil Salom M; Llombart Bosch A
    Arch Esp Urol; 2003 Apr; 56(3):277-85. PubMed ID: 12768988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenes and male breast carcinoma: c-erbB-2 and p53 coexpression predicts a poor survival.
    Pich A; Margaria E; Chiusa L
    J Clin Oncol; 2000 Aug; 18(16):2948-56. PubMed ID: 10944127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proliferative status is a risk index for recurrence in primary superficial (pTa/T1) low-grade urothelial bladder carcinoma.
    Su JS; Arima K; Hasegawa M; Franco OE; Yanagawa M; Sugimura Y; Kawamura J
    Hinyokika Kiyo; 2003 Nov; 49(11):649-58. PubMed ID: 14719452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proliferative activity is a significant prognostic factor in male breast carcinoma.
    Pich A; Margaria E; Chiusa L
    Am J Pathol; 1994 Aug; 145(2):481-9. PubMed ID: 7519830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bag-1 expression as a prognostic factor in tongue squamous cell carcinomas.
    Xie X; Clausen OP; Boysen M
    Laryngoscope; 2004 Oct; 114(10):1785-90. PubMed ID: 15454773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Argyrophilic nucleolar organizer regions (AgNORs) in relation to p53 and bcl-2 protein expression in leukemia patients.
    Klobusická M; Kusenda J; Babusíková O
    Neoplasma; 2003; 50(6):408-15. PubMed ID: 14689061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenes in male breast cancer.
    Idelevich E; Mozes M; Ben-Baruch N; Huszar M; Kruglikova A; Katsnelson R; Shani A
    Am J Clin Oncol; 2003 Jun; 26(3):259-61. PubMed ID: 12796596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nested variant of urothelial carcinoma: a clinicopathologic and immunohistochemical study of 12 cases.
    Lin O; Cardillo M; Dalbagni G; Linkov I; Hutchinson B; Reuter VE
    Mod Pathol; 2003 Dec; 16(12):1289-98. PubMed ID: 14681330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apoptosis in situ, p53, bcl-2 and AgNOR counts as prognostic factors in laryngeal carcinoma.
    Pulkkinen JO; Klemi P; Martikainen P; Grénman R
    Anticancer Res; 1999; 19(1B):703-7. PubMed ID: 10216480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical expression of fatty acid synthase, apoptotic-regulating genes, proliferating factors, and ras protein product in colorectal adenomas, carcinomas, and adjacent nonneoplastic mucosa.
    Visca P; Alò PL; Del Nonno F; Botti C; Trombetta G; Marandino F; Filippi S; Di Tondo U; Donnorso RP
    Clin Cancer Res; 1999 Dec; 5(12):4111-8. PubMed ID: 10632348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different proliferative patterns characterize different preinvasive breast lesions.
    Viacava P; Naccarato AG; Bevilacqua G
    J Pathol; 1999 Jul; 188(3):245-51. PubMed ID: 10419590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical study of apoptosis-related Bcl-2 protein and its correlation with proliferation indices (Ki67, PCNA), tumor suppressor genes (p53, pRb), the oncogene c-erbB-2, sex steroid hormone receptors and other clinicopathological features, in normal, hyperplastic and neoplastic endometrium.
    Mitselou A; Ioachim E; Kitsou E; Vougiouklakis T; Zagorianakou N; Makrydimas G; Stefanaki S; Agnantis NJ
    In Vivo; 2003; 17(5):469-77. PubMed ID: 14598611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications.
    Popov Z; Gil-Diez-De-Medina S; Ravery V; Hoznek A; Bastuji-Garin S; Lefrere-Belda MA; Abbou CC; Chopin DK
    Urol Oncol; 2004; 22(2):93-101. PubMed ID: 15082004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.